Cytokine therapies involving ILC have provided additional options for immunotherapy in pancreatic and gastric cancers, such as dsNKG2D-IL-15, rIL-15, and L19-IL-2; however, ILC have higher efficiency and function. The gene discussed is IL2; the disease is gastric cancer.